Moscow, June 15: AstraZeneca announced on Tuesday that the clinical trial of its long-acting antibody cocktail has not provided evidence of effectiveness in protecting people exposed to the coronavirus.

The trial involved 1,121 adult participants who had been exposed to a person who tested positive for COVID-19 within eight days. The placebo group had 17 cases, while a group where participants were administered with AZD7442 - a combination of two different monoclonal antibodies - had 23. The company noted that the antibody cocktail lowered the risk of developing a symptomatic infection by 33%, which is not a statistically significant result.

"The trial did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 compared to placebo," AstraZeneca said in a statement. Pfizer, AstraZeneca COVID-19 Vaccines Highly Effective Against Delta Variant.

The company promised to publish the results from the trial in a peer-reviewed medical journal. AZD7442 is produced from two long-acting monoclonal antibodies acquired from plasma of convalescent COVID-19 patients.

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)